Nucleus Network
Accelerating Clinical Trials for Improved Health Outcomes

It takes an average of 12 years for a drug to progress from early laboratory discovery to approval for human use. While biotechnology and pharmaceutical companies strive to expedite their novel drugs’ time-to-market, they are often entangled in the quagmire of complex and time-consuming regulatory compulsions. A Melbourneheadquartered company, Nucleus Network, steps up to the challenge with multi-site specialized early phase clinical trial services, enabling biotechnology and pharmaceutical companies to accelerate research translation and improve patients’ health outcomes. With its clinical and regulatory expertise, the company assists biotechnology and pharmaceutical companies in the faster commercialization of new medicines and therapies. To strengthen this workflow, Nucleus Network offers two Phase 1 clinical trial facilities in Australia (Melbourne and Brisbane) and one in the U.S. (Minneapolis). “We are the only multi-site Phase 1 clinical trial organization with clinics in both Australia and the U.S.,” states Cameron Johnson, CEO at Nucleus Network.

While moving from pre-clinical to clinical trials, one of the biggest hindrances for organizations is enrolling volunteers who can participate in the clinical trials. The problem is further exacerbated with the COVID-19-induced lockdowns across the globe, limiting the number of participants available or willing to enrol in a clinical trial. Nucleus Network offers a substantial pool of participants to expedite the clinical trial processes. Along with the area near its facilities, Nucleus Network also sources its volunteers from regional areas to strengthen its pool of volunteers.

The company engages with clients intellectually to understand their requirements and subsequently devise cost and time-efficient commercial and scientific strategies that fit their bill. For instance, drug development companies in the U.S.

must go through lengthy FDA approvals such as time-consuming investigational new drug (IND) applications to initiate their clinical trials. To this end, Nucleus Network assists clients to start their early phase clinical trials in Australia as the country has one of the fastest jurisdictions in terms of clinical trial approval. Besides, along with first-in-human studies, the company also runs highly complex patient studies—one of the few organizations in the U.S. that can run complex hepatic and renal patient studies—through its network of physicians.

More importantly, the three facilities of Nucleus Network are strategically co-located within hospitals or research precincts, enabling the company to conduct highly complex biomarker assessments such as bronchoscopy, endoscopy and lumbar punctures, among others. Further, the hospitals and research precincts also provide specialized pharmacodynamic assessments of the drug, allowing clients to analyze their investigational drugs better.

We are the only multi-site Phase 1 clinical trial organization with clinics in Australia and the U.S.

With over 20 years of experience in conducting early phase clinical trials, Nucleus Network has stood the test of time by staying on top of the evolving clinical trials landscape. Along the way, the company has secured impeccable client satisfaction by conducting more than 1000 phase 1 clinical trials for clients across the globe, including the U.S., China, Europe, Japan, South Korea, and Taiwan, in a time and costefficient manner. A testimony to Nucleus Network’s exemplary service is the success story of a U.S.-based company that wanted the fastest jurisdiction and to recruit renal patients for their program promptly. Nucleus Network assisted the company in getting into the clinic quickly through Australian jurisdiction and subsequently assisted them in executing patient trials in the U.S. at its Minneapolis facility that specializes in conducting renal and hepatic insufficiency studies.

Last year, Nucleus Network was acquired by Blackstone, a leading global investment organization with $7 billion in assets on its Life Sciences investment platform (BXLS). Nucleus Network intends to leverage Blackstone’s expansive worldwide network and significant experience in the life sciences sector to accelerate its next phase of global growth in phase one clinical trial delivery and fulfill its vision of “Advancing medicine, improving lives.”